---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-08T20:27:44.778347'
end_time: '2026-02-08T20:33:05.172960'
duration_seconds: 320.39
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PDCD5
  gene_symbol: PDCD5
  uniprot_accession: O14737
  protein_description: 'RecName: Full=Programmed cell death protein 5; AltName: Full=TF-1
    cell apoptosis-related protein 19; Short=Protein TFAR19;'
  gene_info: Name=PDCD5; Synonyms=TFAR19;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the PDCD5 family. .
  protein_domains: PDCD5-like. (IPR002836); PDCD5-like_sf. (IPR036883); dsDNA_bind
    (PF01984)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 16
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O14737
- **Protein Description:** RecName: Full=Programmed cell death protein 5; AltName: Full=TF-1 cell apoptosis-related protein 19; Short=Protein TFAR19;
- **Gene Information:** Name=PDCD5; Synonyms=TFAR19;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the PDCD5 family. .
- **Key Domains:** PDCD5-like. (IPR002836); PDCD5-like_sf. (IPR036883); dsDNA_bind (PF01984)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PDCD5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PDCD5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PDCD5** (gene ID: PDCD5, UniProt: O14737) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O14737
- **Protein Description:** RecName: Full=Programmed cell death protein 5; AltName: Full=TF-1 cell apoptosis-related protein 19; Short=Protein TFAR19;
- **Gene Information:** Name=PDCD5; Synonyms=TFAR19;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the PDCD5 family. .
- **Key Domains:** PDCD5-like. (IPR002836); PDCD5-like_sf. (IPR036883); dsDNA_bind (PF01984)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PDCD5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PDCD5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PDCD5** (gene ID: PDCD5, UniProt: O14737) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
- Objective 1 (verification): Completed. The literature cited below explicitly studies human PDCD5/TFAR19 and its role in TP53 signaling, matching the provided UniProt identity and organism. (kim2024jmjd4promotestumor pages 1-2, kim2024jmjd4promotestumor pages 6-6)
- Objective 2 (recent sources) through Objective 6 (synthesis): Completed using 2023–2024 primary and clinical studies and one 2023 mechanistic review relevant to PDCD5 regulation and disease associations. (kim2024jmjd4promotestumor pages 1-2, fu2023theregulationand pages 6-8, peng2023dihydroartemisininenhancesthe pages 14-16, kim2024jmjd4promotestumor pages 2-3, fu2023theregulationand pages 4-6, kim2024jmjd4promotestumor pages 3-5, xiao2023pdcd5asa pages 1-2, xiao2023pdcd5asa pages 6-8, xiao2023pdcd5asa pages 12-14, xiao2023pdcd5asa pages 14-15)

Comprehensive research report: Human PDCD5 (TFAR19; UniProt O14737)

1) Key concepts and current definitions
- Identity and nomenclature: Programmed cell death protein 5 (PDCD5), also known as TFAR19, is a human protein broadly implicated in regulation of apoptosis and stress responses. 2024 mechanistic work explicitly uses human PDCD5/TFAR19 nomenclature and places PDCD5 upstream of TP53-mediated apoptosis, supporting the identity provided. URL: https://doi.org/10.5483/bmbrep.2024-0027 (published July 2024). (kim2024jmjd4promotestumor pages 1-2, kim2024jmjd4promotestumor pages 6-6)
- Core functional concept: PDCD5 promotes TP53 (p53) tumor-suppressor activity during genotoxic stress by stabilizing TP53 signaling outputs and enhancing expression of pro-apoptotic targets (e.g., BAX, PUMA). Mechanistically, PDCD5 levels and localization are dynamically regulated after DNA damage. URL: https://doi.org/10.5483/bmbrep.2024-0027 (2024); https://doi.org/10.3390/cells12081161 (2023). (kim2024jmjd4promotestumor pages 2-3, fu2023theregulationand pages 4-6)
- Subcellular localization dynamics: PDCD5 undergoes cytoplasm-to-nucleus translocation during apoptosis; nuclear PDCD5 has been described as an early apoptotic signal. In colon cancer models, dihydroartemisinin (DHA) triggers changes in PDCD5 subcellular distribution detectable by immunocytochemistry and fractionation. URL: https://doi.org/10.5483/bmbrep.2024-0027 (2024); https://doi.org/10.21203/rs.3.rs-3353635/v1 (preprint posted Sept 2023). (kim2024jmjd4promotestumor pages 6-6, peng2023dihydroartemisininenhancesthe pages 14-16)

2) Recent developments and latest research (2023–2024)
- JMJD4 as a negative regulator of PDCD5 (2024): Kim et al. identified JMJD4 as a direct PDCD5-binding protein by LC–MS, mapped the interaction (PDCD5 aa 91–125; JMJD4 aa 180–221), and showed JMJD4 lowers PDCD5 protein levels post-transcriptionally via proteasome-dependent degradation. JMJD4 overexpression reduced TP53, BAX, and PUMA under genotoxic stress, promoting proliferation and chemoresistance; JMJD4 knockdown had opposite effects. Clinical datasets linked high JMJD4 to poorer survival in colon and lung cancer. URL: https://doi.org/10.5483/bmbrep.2024-0027 (July 2024). (kim2024jmjd4promotestumor pages 1-2, kim2024jmjd4promotestumor pages 2-3, kim2024jmjd4promotestumor pages 3-5)
- OTUD5 as a positive regulator of PDCD5 stability (2023 review synthesizing primary studies): Under genotoxic stress, the deubiquitinase OTUD5 binds and deubiquitinates PDCD5, stabilizing it and enabling sequential activation of PDCD5 and TP53. OTUD5 depletion reduces PDCD5 and TP53 activation and confers resistance to chemotherapeutics in NSCLC models; overexpression has the inverse effect. URL: https://doi.org/10.3390/cells12081161 (April 2023). (fu2023theregulationand pages 6-8, fu2023theregulationand pages 4-6)
- PDCD5/ARAF axis in colon cancer and drug response (2023 preprint): In patient tissues (n=14) and cell/xenograft models, PDCD5 was lower in tumors versus adjacent tissues, suppressed proliferation and tumorigenicity, and enhanced oxaliplatin cytotoxicity. DHA increased PDCD5 nuclear localization and suppressed ARAF/MEK/ERK signaling, improving oxaliplatin effects via a PDCD5-dependent mechanism. URL: https://doi.org/10.21203/rs.3.rs-3353635/v1 (Sept 2023). (peng2023dihydroartemisininenhancesthe pages 14-16)

3) Functions, pathways, and localization in cellular context
- TP53 signaling and apoptosis: PDCD5 enhances TP53-mediated apoptosis under DNA-damage stress, increasing pro-apoptotic targets (e.g., BAX, PUMA) while lowering anti-apoptotic programs. Regulation of PDCD5 protein stability is central: OTUD5 deubiquitinates/stabilizes PDCD5, while JMJD4 promotes its proteasomal degradation. These opposing controls position PDCD5 as a convergence node integrating ubiquitin signaling with TP53-dependent apoptosis. URLs: 2024 BMB Reports https://doi.org/10.5483/bmbrep.2024-0027; 2023 Cells review https://doi.org/10.3390/cells12081161. (kim2024jmjd4promotestumor pages 1-2, kim2024jmjd4promotestumor pages 2-3, fu2023theregulationand pages 4-6)
- Nuclear translocation and site-of-action: During apoptosis or under certain therapeutic cues (e.g., DHA), PDCD5 accumulates in the nucleus, consistent with a role in chromatin- and transcription-coupled death programs. This nuclear localization is experimentally demonstrated by imaging and biochemical fractionation in colon cancer cells treated with DHA. URL: https://doi.org/10.21203/rs.3.rs-3353635/v1 (2023). (peng2023dihydroartemisininenhancesthe pages 14-16)
- Additional pathway links (colon cancer context): PDCD5 negatively influences ARAF/MEK/ERK signaling; functional rescue experiments indicate PDCD5-dependent suppression of ARAF contributes to anti-proliferative and chemosensitizing effects. URL: https://doi.org/10.21203/rs.3.rs-3353635/v1 (2023). (peng2023dihydroartemisininenhancesthe pages 14-16)

4) Disease associations, biomarkers, and real-world implementations
- Rheumatoid arthritis (RA) biomarker (2023 clinical study): In 152 newly diagnosed RA patients and 38 healthy controls, PDCD5 expression in blood was higher in active RA than in remission or controls. PDCD5 predicted remission with AUC 0.846 (95% CI 0.780–0.912); specificity 88.1%, sensitivity 86.6%. Higher PDCD5 associated with increased incidence risk (OR 1.73, 95% CI 1.45–1.98, P=0.005); a high-risk PDCD5 group had 2.94-fold greater incidence risk (95% CI 2.35–4.62, P<0.001). PDCD5 correlated with FOXP3, TNF-α, IL-17A, IFN-γ, IL-6, and clinical indices (IgG, RF, CRP, ESR, anti-CCP, DAS28). These data support PDCD5 as a candidate blood biomarker to stratify RA disease activity and remission probability. URL: https://doi.org/10.1007/s40744-023-00587-5 (Aug 2023). (xiao2023pdcd5asa pages 1-2, xiao2023pdcd5asa pages 6-8, xiao2023pdcd5asa pages 12-14, xiao2023pdcd5asa pages 14-15)
- Oncology relevance (2023–2024): PDCD5 levels are frequently reduced in tumors, and its forced downregulation by JMJD4 promotes proliferation and chemoresistance; conversely, stabilizing PDCD5 (e.g., by OTUD5) or promoting its nuclear function enhances TP53-mediated apoptosis. In colorectal models, manipulating PDCD5 modulates sensitivity to oxaliplatin, and DHA augments PDCD5 nuclear localization and suppresses MAPK signaling. Together, these observations nominate PDCD5 and its regulators (JMJD4, OTUD5) as translational targets for chemosensitization strategies. URLs: https://doi.org/10.5483/bmbrep.2024-0027 (2024); https://doi.org/10.21203/rs.3.rs-3353635/v1 (2023); https://doi.org/10.3390/cells12081161 (2023). (kim2024jmjd4promotestumor pages 1-2, peng2023dihydroartemisininenhancesthe pages 14-16, kim2024jmjd4promotestumor pages 2-3, fu2023theregulationand pages 4-6, kim2024jmjd4promotestumor pages 3-5)

5) Expert opinions and mechanistic analysis from authoritative sources
- 2024 primary study (BMB Reports): Provides direct biochemical and cell-biological evidence that JMJD4 binds PDCD5 and lowers its protein stability to inhibit TP53-dependent apoptosis. The authors propose JMJD4 as a cancer-promoting factor via the PDCD5–TP53 axis and a potential therapeutic target, implying that PDCD5 protein stabilization could be beneficial in therapy. URL: https://doi.org/10.5483/bmbrep.2024-0027 (July 2024). (kim2024jmjd4promotestumor pages 1-2, kim2024jmjd4promotestumor pages 2-3, kim2024jmjd4promotestumor pages 3-5)
- 2023 mechanistic synthesis (OTUD5 review in Cells): Assembles evidence that OTUD5 deubiquitinates and stabilizes PDCD5 and TP53 under DNA damage, enabling rapid TP53 activation and apoptosis. This positions DUBs and the ubiquitin system as tuners of PDCD5-driven death signaling, suggesting druggability at the level of DUBs or E3 ligases controlling PDCD5. URL: https://doi.org/10.3390/cells12081161 (April 2023). (fu2023theregulationand pages 6-8, fu2023theregulationand pages 4-6)
- 2023 clinical RA study (Rheumatology and Therapy): Argues for PDCD5 as a practical blood biomarker with strong ROC characteristics and correlations to immunologic mediators, pointing to potential utility in monitoring disease activity and remission. URL: https://doi.org/10.1007/s40744-023-00587-5 (Aug 2023). (xiao2023pdcd5asa pages 1-2, xiao2023pdcd5asa pages 6-8)

6) Relevant statistics and data (selected 2023–2024)
- RA biomarker performance: AUC 0.846 (95% CI 0.780–0.912); sensitivity 86.6%; specificity 88.1%. Incidence risk per higher PDCD5: OR 1.73 (95% CI 1.45–1.98, P=0.005); high-risk group OR 2.94 (95% CI 2.35–4.62, P<0.001). URL: https://doi.org/10.1007/s40744-023-00587-5 (2023). (xiao2023pdcd5asa pages 6-8)
- Colon cancer cohort and model details: Tumor versus adjacent tissue analysis in 14 patients; PDCD5 overexpression/knockdown validated in HCT116 and RKO; in vivo xenograft data in BALB/c nude mice; DHA induced PDCD5 nuclear enrichment and enhanced oxaliplatin efficacy via PDCD5–ARAF pathway modulation. URL: https://doi.org/10.21203/rs.3.rs-3353635/v1 (2023). (peng2023dihydroartemisininenhancesthe pages 14-16)
- JMJD4–PDCD5 interaction mapping and impact: Direct binding mapped to JMJD4 aa 180–221 and PDCD5 aa 91–125; JMJD4 overexpression decreased PDCD5 protein without changing mRNA; proteasome dependence demonstrated; TP53 targets (BAX, PUMA) reduced upon JMJD4 overexpression under genotoxic stress. URL: https://doi.org/10.5483/bmbrep.2024-0027 (2024). (kim2024jmjd4promotestumor pages 2-3)

7) Clarifications on catalytic activity and molecular role
- PDCD5 is not an enzyme or transporter; it functions as a regulatory adaptor/scaffold whose abundance and localization tune pro-apoptotic transcriptional programs, especially in the TP53 pathway. Evidence supports direct and indirect actions: (i) protein–protein interactions that influence TP53 stability/output; (ii) coupling to ubiquitin signaling via DUBs (OTUD5) and degradation factors (JMJD4) that set PDCD5 protein steady-state; and (iii) subcellular relocalization to the nucleus during apoptotic signaling. URLs: 2024 BMB Reports https://doi.org/10.5483/bmbrep.2024-0027; 2023 Cells review https://doi.org/10.3390/cells12081161; 2023 Research Square preprint https://doi.org/10.21203/rs.3.rs-3353635/v1. (kim2024jmjd4promotestumor pages 1-2, kim2024jmjd4promotestumor pages 2-3, fu2023theregulationand pages 4-6, peng2023dihydroartemisininenhancesthe pages 14-16)

Limitations and open questions
- Structural and domain annotations (e.g., PDCD5-like domain, dsDNA_bind PF01984) and canonical Tip60/TP53 acetylation biochemistry were not retrievable within the 2023–2024 sources gathered here; however, the 2024 and 2023 studies provide convergent mechanistic evidence on PDCD5’s regulation of TP53-mediated apoptosis and on its nuclear relocalization under stress. Additional structural/domain confirmation would require consultation of curated databases or primary structural papers beyond the present evidence set. (kim2024jmjd4promotestumor pages 1-2, fu2023theregulationand pages 4-6)

Conclusions
PDCD5 (TFAR19) in humans is a nuclear-translocating, apoptosis-facilitating regulator that potentiates TP53-dependent death programs under genotoxic stress. Its activity is tuned by opposing ubiquitin-pathway regulators: OTUD5 stabilizes PDCD5 by deubiquitination, whereas JMJD4 promotes proteasomal degradation, collectively dictating TP53 output and chemosensitivity. Clinically, PDCD5 shows promise as a blood biomarker of rheumatoid arthritis activity and remission with strong performance metrics, and in oncology models PDCD5 status modulates response to chemotherapeutics and MAPK signaling via ARAF, suggesting actionable translational avenues. URLs: 2024 BMB Reports https://doi.org/10.5483/bmbrep.2024-0027; 2023 Cells review https://doi.org/10.3390/cells12081161; 2023 Rheumatology and Therapy https://doi.org/10.1007/s40744-023-00587-5; 2023 Research Square preprint https://doi.org/10.21203/rs.3.rs-3353635/v1. (kim2024jmjd4promotestumor pages 1-2, fu2023theregulationand pages 6-8, peng2023dihydroartemisininenhancesthe pages 14-16, kim2024jmjd4promotestumor pages 2-3, fu2023theregulationand pages 4-6, kim2024jmjd4promotestumor pages 3-5, xiao2023pdcd5asa pages 1-2, xiao2023pdcd5asa pages 6-8, xiao2023pdcd5asa pages 12-14, xiao2023pdcd5asa pages 14-15)

References

1. (kim2024jmjd4promotestumor pages 1-2): Hyunsik Kim, Subhin Jang, Soo Yeon Lee, Jae-Hwan Kwon, Seunghee Byun, Jung-Yoon Yoo, Sungryul Yu, Soo-Yeon Park, and Ho-Geun Yoon. Jmjd4 promotes tumor progression via inhibition of the pdcd5-tp53 pathway. BMB Reports, 58:64-69, Jul 2024. URL: https://doi.org/10.5483/bmbrep.2024-0027, doi:10.5483/bmbrep.2024-0027. This article has 0 citations and is from a peer-reviewed journal.

2. (kim2024jmjd4promotestumor pages 6-6): Hyunsik Kim, Subhin Jang, Soo Yeon Lee, Jae-Hwan Kwon, Seunghee Byun, Jung-Yoon Yoo, Sungryul Yu, Soo-Yeon Park, and Ho-Geun Yoon. Jmjd4 promotes tumor progression via inhibition of the pdcd5-tp53 pathway. BMB Reports, 58:64-69, Jul 2024. URL: https://doi.org/10.5483/bmbrep.2024-0027, doi:10.5483/bmbrep.2024-0027. This article has 0 citations and is from a peer-reviewed journal.

3. (fu2023theregulationand pages 6-8): Lin Fu, Kun Lu, Qian Jiao, Xi Chen, and Fengju Jia. The regulation and double-edged roles of the deubiquitinase otud5. Cells, 12:1161, Apr 2023. URL: https://doi.org/10.3390/cells12081161, doi:10.3390/cells12081161. This article has 18 citations and is from a poor quality or predatory journal.

4. (peng2023dihydroartemisininenhancesthe pages 14-16): Yanling Peng, Yingying Zheng, Juanjuan Qiu, Jing Liu, Jiaorui Zou, Chunyan Liu, and Zhengbin Chai. Dihydroartemisinin enhances the effects of oxaliplatin by activating pdcd5/araf mediated signal transduction in colon cancer. Sep 2023. URL: https://doi.org/10.21203/rs.3.rs-3353635/v1, doi:10.21203/rs.3.rs-3353635/v1.

5. (kim2024jmjd4promotestumor pages 2-3): Hyunsik Kim, Subhin Jang, Soo Yeon Lee, Jae-Hwan Kwon, Seunghee Byun, Jung-Yoon Yoo, Sungryul Yu, Soo-Yeon Park, and Ho-Geun Yoon. Jmjd4 promotes tumor progression via inhibition of the pdcd5-tp53 pathway. BMB Reports, 58:64-69, Jul 2024. URL: https://doi.org/10.5483/bmbrep.2024-0027, doi:10.5483/bmbrep.2024-0027. This article has 0 citations and is from a peer-reviewed journal.

6. (fu2023theregulationand pages 4-6): Lin Fu, Kun Lu, Qian Jiao, Xi Chen, and Fengju Jia. The regulation and double-edged roles of the deubiquitinase otud5. Cells, 12:1161, Apr 2023. URL: https://doi.org/10.3390/cells12081161, doi:10.3390/cells12081161. This article has 18 citations and is from a poor quality or predatory journal.

7. (kim2024jmjd4promotestumor pages 3-5): Hyunsik Kim, Subhin Jang, Soo Yeon Lee, Jae-Hwan Kwon, Seunghee Byun, Jung-Yoon Yoo, Sungryul Yu, Soo-Yeon Park, and Ho-Geun Yoon. Jmjd4 promotes tumor progression via inhibition of the pdcd5-tp53 pathway. BMB Reports, 58:64-69, Jul 2024. URL: https://doi.org/10.5483/bmbrep.2024-0027, doi:10.5483/bmbrep.2024-0027. This article has 0 citations and is from a peer-reviewed journal.

8. (xiao2023pdcd5asa pages 1-2): Juan Xiao, Fengqiao Zhou, Zhenwang Zhao, Fengsheng Cao, Hong Xiao, Lu Zhang, Huabo Chen, Ke Wang, and Anbing Zhang. Pdcd5 as a potential biomarker for improved prediction of the incidence and remission for patients with rheumatoid arthritis. Rheumatology and Therapy, 10:1369-1383, Aug 2023. URL: https://doi.org/10.1007/s40744-023-00587-5, doi:10.1007/s40744-023-00587-5. This article has 0 citations and is from a peer-reviewed journal.

9. (xiao2023pdcd5asa pages 6-8): Juan Xiao, Fengqiao Zhou, Zhenwang Zhao, Fengsheng Cao, Hong Xiao, Lu Zhang, Huabo Chen, Ke Wang, and Anbing Zhang. Pdcd5 as a potential biomarker for improved prediction of the incidence and remission for patients with rheumatoid arthritis. Rheumatology and Therapy, 10:1369-1383, Aug 2023. URL: https://doi.org/10.1007/s40744-023-00587-5, doi:10.1007/s40744-023-00587-5. This article has 0 citations and is from a peer-reviewed journal.

10. (xiao2023pdcd5asa pages 12-14): Juan Xiao, Fengqiao Zhou, Zhenwang Zhao, Fengsheng Cao, Hong Xiao, Lu Zhang, Huabo Chen, Ke Wang, and Anbing Zhang. Pdcd5 as a potential biomarker for improved prediction of the incidence and remission for patients with rheumatoid arthritis. Rheumatology and Therapy, 10:1369-1383, Aug 2023. URL: https://doi.org/10.1007/s40744-023-00587-5, doi:10.1007/s40744-023-00587-5. This article has 0 citations and is from a peer-reviewed journal.

11. (xiao2023pdcd5asa pages 14-15): Juan Xiao, Fengqiao Zhou, Zhenwang Zhao, Fengsheng Cao, Hong Xiao, Lu Zhang, Huabo Chen, Ke Wang, and Anbing Zhang. Pdcd5 as a potential biomarker for improved prediction of the incidence and remission for patients with rheumatoid arthritis. Rheumatology and Therapy, 10:1369-1383, Aug 2023. URL: https://doi.org/10.1007/s40744-023-00587-5, doi:10.1007/s40744-023-00587-5. This article has 0 citations and is from a peer-reviewed journal.

## Citations

1. peng2023dihydroartemisininenhancesthe pages 14-16
2. fu2023theregulationand pages 6-8
3. fu2023theregulationand pages 4-6
4. https://doi.org/10.5483/bmbrep.2024-0027
5. https://doi.org/10.3390/cells12081161
6. https://doi.org/10.21203/rs.3.rs-3353635/v1
7. https://doi.org/10.5483/bmbrep.2024-0027;
8. https://doi.org/10.3390/cells12081161.
9. https://doi.org/10.1007/s40744-023-00587-5
10. https://doi.org/10.3390/cells12081161;
11. https://doi.org/10.21203/rs.3.rs-3353635/v1.
12. https://doi.org/10.1007/s40744-023-00587-5;
13. https://doi.org/10.5483/bmbrep.2024-0027,
14. https://doi.org/10.3390/cells12081161,
15. https://doi.org/10.21203/rs.3.rs-3353635/v1,
16. https://doi.org/10.1007/s40744-023-00587-5,